Vireo Growth (VREOD) & The Competition Critical Review

Vireo Growth (OTCMKTS:VREOD) is one of 906 public companies in the “Pharmaceuticals” industry, but how does it contrast to its peers? We will compare Vireo Growth to similar companies based on the strength of its valuation, earnings, analyst recommendations, institutional ownership, profitability, dividends and risk.

Profitability

This table compares Vireo Growth and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Vireo Growth	-23.37%	-19.76%	-7.15%
Vireo Growth Competitors	-2,303.77%	-221.69%	-17.78%

Insider & Institutional Ownership

32.8% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 3.8% of Vireo Growth shares are owned by company insiders. Comparatively, 14.2% of shares of all “Pharmaceuticals” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Earnings and Valuation

This table compares Vireo Growth and its peers gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Vireo Growth	$268.77 million	-$68.11 million	-3.02
Vireo Growth Competitors	$3.48 billion	$3.12 billion	545.72

Vireo Growth’s peers have higher revenue and earnings than Vireo Growth. Vireo Growth is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Volatility & Risk

Vireo Growth has a beta of 1.78, suggesting that its stock price is 78% more volatile than the S&P 500. Comparatively, Vireo Growth’s peers have a beta of -3.18, suggesting that their average stock price is 418% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings and recommmendations for Vireo Growth and its peers, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vireo Growth	1	0	0	0	1.00
Vireo Growth Competitors	7719	13663	25550	994	2.41

As a group, “Pharmaceuticals” companies have a potential upside of 30.63%. Given Vireo Growth’s peers stronger consensus rating and higher probable upside, analysts plainly believe Vireo Growth has less favorable growth aspects than its peers.

Summary

Vireo Growth peers beat Vireo Growth on 9 of the 13 factors compared.

Vireo Growth Company Profile

Goodness Growth Holdings, Inc. operates as a cannabis company in the United States. The company cultivates, processes, and distributes medical and adult-use cannabis products. It sells cannabis products through its network of Green Goods and other Goodness Growth branded retail dispensaries and third-party dispensaries in Maryland, Minnesota, and New York. The company was formerly known as Vireo Health International Inc. and changed its name to Goodness Growth Holdings, Inc. in June 2021. Goodness Growth Holdings, Inc. is headquartered in Minneapolis, Minnesota.